MARKET

BIAFW

BIAFW

bioAffinity Tech
NASDAQ
0.1281
-0.0019
-1.46%
Closed 09:30 07/02 EDT
OPEN
0.1281
PREV CLOSE
0.1300
HIGH
0.1281
LOW
0.1281
VOLUME
1.97K
TURNOVER
--
52 WEEK HIGH
0.8121
52 WEEK LOW
0.0525
MARKET CAP
--
P/E (TTM)
-0.0113
1D
5D
1M
3M
1Y
5Y
1D
bioAffinity Highlights Surge in CyPath Lung Test Adoption
TipRanks · 4d ago
bioAffinity to join NAVREF-hosted webinar on Philips-led US veterans lung screening program
PUBT · 4d ago
Q2 Virtual Investor Summit Presentations Now Available On Demand
Barchart · 4d ago
Weekly Report: what happened at BIAF last week (0622-0626)?
Weekly Report · 5d ago
BioAffinity will present preclinical findings on small interfering RNAs
TipRanks · 06/22 12:09
bioAffinity To Present Preclinical Findings For Therapeutic Approach That Uses siRNAs That Kill Squamous And Basal Skin Cancer Cells In Vitro At 2026 RNA Therapeutics Symposium
Benzinga · 06/22 12:07
bioAffinity reports positive preclinical data for siRNA therapy targeting squamous, basal skin cancer cells
PUBT · 06/22 12:01
BIOAFFINITY TECHNOLOGIES REPORTS POSITIVE PRECLINICAL FINDINGS SHOWING PROPRIETARY GENE SILENCING TECHNOLOGY IS SELECTIVELY CYTOTOXIC TO SQUAMOUS SKIN CANCER CELLS WITHOUT HARMING HEALTHY CELLS
Reuters · 06/22 12:00
More
About BIAFW
bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.

Webull offers bioAffinity Technologies Inc stock information, including NASDAQ: BIAFW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIAFW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIAFW stock methods without spending real money on the virtual paper trading platform.